Prolonged survival of mice with multiple liver metastases of human colon cancer by intravenous administration of replicable E1B-55K-deleted adenovirus with E1A expressed by CEA promoter

Liver is the most preferential site for metastasis of colon cancer. We, in the present study, constructed a self-replicable adenovirus in which E1A is driven by a CEA promoter and E1B-55K is deleted from the E1B region (AdCEAp/Rep) and examined its effects on multiple metastases of a human colon can...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Molecular therapy 2004-12, Vol.10 (6), p.1043-1050
Hauptverfasser:	Sagawa, Tamotsu, Takahashi, Minoru, Sato, Tsutomu, Sato, Yasushi, Lu, Yue, Sumiyoshi, Tetsuya, Yamada, Yasuyuki, Iyama, Satoshi, Fukaura, Junki, Sasaki, Katsunori, Hamada, Hirofumi, Miyanishi, Koji, Takayama, Tetsuji, Kato, Junji, Niitsu, Yoshiro
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenoviridae - genetics Adenoviridae - physiology Adenovirus E1A Proteins - genetics Adenovirus E1A Proteins - metabolism Adenovirus E1B Proteins - deficiency Adenovirus E1B Proteins - genetics Adenoviruses Animals Cancer therapies Carcinoembryonic Antigen - analysis Carcinoembryonic Antigen - biosynthesis Carcinoembryonic Antigen - genetics Colonic Neoplasms - genetics Colonic Neoplasms - pathology Colonic Neoplasms - therapy Colorectal cancer Cytotoxicity Disease Models, Animal Female Gene Deletion Gene therapy Genetic Therapy Hepatocytes - metabolism Humans Infections Infusions, Intravenous Liver Liver Neoplasms - genetics Liver Neoplasms - pathology Liver Neoplasms - secondary Liver Neoplasms - therapy Medical prognosis Medical research Metastasis Mice Neoplasm Transplantation Promoter Regions, Genetic - genetics Skin Neoplasms - genetics Skin Neoplasms - pathology Skin Neoplasms - secondary Skin Neoplasms - therapy Survival Rate Time Factors Tumor Cells, Cultured Tumors Virus Replication
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!